{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:28:31Z","timestamp":1776418111532,"version":"3.51.2"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Conseller\u00eda de Sanitat Universal i Salut P\u00fablica (Generalitat Valenciana, Spain)","award":["UGP-21-410"],"award-info":[{"award-number":["UGP-21-410"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Introduction. There is negligible evidence on the efficacy of ivermectin for treating COVID-19 pneumonia. This study aimed to assess the efficacy of ivermectin for pre-emptively treating Strongyloides stercoralis hyperinfection syndrome in order to reduce mortality and the need for respiratory support in patients hospitalized for COVID-19. Methods. This single-center, observational, retrospective study included patients admitted with COVID-19 pneumonia at Hospital Vega Baja from 23 February 2020 to 14 March 2021. Because strongyloidiasis is endemic to our area, medical criteria support empiric administration of a single, 200 \u03bcg\/kg dose of ivermectin to prevent Strongyloides hyperinfection syndrome. The outcome was a composite of all-cause in-hospital mortality and the need for respiratory support. Results. Of 1167 patients in the cohort, 96 received ivermectin. After propensity score matching, we included 192 patients. The composite outcome of in-hospital mortality or need for respiratory support occurred in 41.7% of the control group (40\/96) and 34.4% (33\/96) of the ivermectin group. Ivermectin was not associated with the outcome of interest (adjusted odds ratio [aOR] 0.77, 95% confidence interval [CI] 0.35, 1.69; p = 0.52). The factors independently associated with this endpoint were oxygen saturation (aOR 0.78, 95% CI 0.68, 0.89, p &lt; 0.001) and C-reactive protein at admission (aOR: 1.09, 95% CI 1.03, 1.16, p &lt; 0.001). Conclusions. In hospitalized patients with COVID-19 pneumonia, ivermectin at a single dose for pre-emptively treating Strongyloides stercoralis is not effective in reducing mortality or the need for respiratory support measures.<\/jats:p>","DOI":"10.3390\/v15051138","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:37:09Z","timestamp":1683769029000},"page":"1138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-7706","authenticated-orcid":false,"given":"Jara","family":"Llenas-Garc\u00eda","sequence":"first","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"},{"name":"Clinical Medicine Department, Miguel Hern\u00e1ndez University, 03202 Elche, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6991-923X","authenticated-orcid":false,"given":"Alfonso","family":"del Pozo","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-8083","authenticated-orcid":false,"given":"Alberto","family":"Talaya","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Roig-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6217-6077","authenticated-orcid":false,"given":"Noem\u00ed","family":"Poveda Ruiz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Reina Sof\u00eda, 30003 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-5124","authenticated-orcid":false,"given":"Carlos","family":"Devesa Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Hospital Vega Baja, 03314 Orihuela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Borrajo Brunete","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Vega Baja, 03314 Orihuela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-7823","authenticated-orcid":false,"given":"Inmaculada","family":"Gonz\u00e1lez Cuello","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lucas Dato","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Vega Baja, 03314 Orihuela, Spain"},{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7727-1587","authenticated-orcid":false,"given":"Miriam","family":"Navarro","sequence":"additional","affiliation":[{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"},{"name":"Epidemiology Unit, Public Health Centre, 03202 Elche, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Wikman-Jorgensen","sequence":"additional","affiliation":[{"name":"Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain"},{"name":"Internal Medicine Service, Elda General University Hospital, 03600 Elda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","unstructured":"WHO Coronavirus (COVID-19) Dashboard (2022, November 02). WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","unstructured":"Clinical Spectrum (2022, November 02). COVID-19 Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4269\/ajtmh.20-0995","article-title":"Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19","volume":"103","author":"Rayner","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin Is a Specific Inhibitor of Importin \u03b1\/\u03b2-Mediated Nuclear Import Able to Inhibit Replication of HIV-1 and Dengue Virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.21873\/invivo.12134","article-title":"Ivermectin Docks to the SARS-CoV-2 Spike Receptor-Binding Domain Attached to ACE2","volume":"34","author":"Lehrer","year":"2020","journal-title":"In Vivo"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMc2114907","article-title":"Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19","volume":"385","author":"Temple","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","article-title":"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines","volume":"28","author":"Bryant","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1097\/MJT.0000000000001482","article-title":"Expression of Concern for Bryant a, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S., Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4): E434-E460","volume":"29","author":"Manu","year":"2022","journal-title":"Am. J. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Popp, M., Stegemann, M., Metzendorf, M.I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., and Weibel, S. (2021). Ivermectin for Preventing and Treating COVID-19. Cochrane Database Syst. Rev., 7.","DOI":"10.1002\/14651858.CD015017"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E223079","DOI":"10.1001\/jamanetworkopen.2022.3079","article-title":"Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis: A Meta-Analysis","volume":"5","author":"Bitterman","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Colosimo, M., Caroleo, M.C., Caruso, A., Luciani, F., Cione, E., Talarico, G., Vescio, V., Sarro, G.D., Minchella, P., and Nistic\u00f2, S. (2022). Fatal Case of Autochthonous Strongyloides Stercoralis Hyperinfection in an Immunosuppressed Calabrian Patient. Reports, 5.","DOI":"10.3390\/reports5040047"},{"key":"ref_13","first-page":"954","article-title":"Eosinophilic Myocarditis in a Patient With Strongyloides Stercoralis Infection","volume":"3","author":"Dimitroglou","year":"2021","journal-title":"Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dato, A.L., Pacheco-Tenza, M.I., Brunete, E.B., L\u00f3pez, B.M., L\u00f3pez, M.G., Cuello, I.G., Colom\u00e9, J.G., Cots, M.N., Saugar, J.M., and Garc\u00eda-Vazquez, E. (2020). Strongyloidiasis in Southern Alicante (Spain): Comparative Retrospective Study of Autochthonous and Imported Cases. Pathogens, 9.","DOI":"10.3390\/pathogens9080601"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/thoraxjnl-2020-216001","article-title":"Development and Validation of a Prediction Model for 30-Day Mortality in Hospitalised Patients with COVID-19: The COVID-19 SEIMC Score","volume":"76","author":"Berenguer","year":"2021","journal-title":"Thorax"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study","volume":"159","author":"Rajter","year":"2021","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2022.0189","article-title":"Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial","volume":"182","author":"Lim","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.2022.18590","article-title":"Effect of Ivermectin vs. Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"328","author":"Naggie","year":"2022","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Vallejos, J., Zoni, R., Bangher, M., Villamandos, S., Bobadilla, A., Plano, F., Campias, C., Chaparro Campias, E., Medina, M.F., and Achinelli, F. (2021). Ivermectin to Prevent Hospitalizations in Patients with COVID-19 (IVERCOR-COVID19) a Randomized, Double-Blind, Placebo-Controlled Trial. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06348-5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial","volume":"325","author":"Hurtado","year":"2021","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106516","DOI":"10.1016\/j.ijantimicag.2021.106516","article-title":"High-Dose Ivermectin for Early Treatment of COVID-19 (COVER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof-of-Concept Clinical Trial","volume":"59","author":"Buonfrate","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A Five-Day Course of Ivermectin for the Treatment of COVID-19 May Reduce the Duration of Illness","volume":"103","author":"Ahmed","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/20477724.2021.1890887","article-title":"Phase 2 Randomized Study on Chloroquine, Hydroxychloroquine or Ivermectin in Hospitalized Patients with Severe Manifestations of SARS-CoV-2 Infection","volume":"115","author":"Galan","year":"2021","journal-title":"Pathog. Glob. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"03000605211013550","DOI":"10.1177\/03000605211013550","article-title":"Ivermectin in Combination with Doxycycline for Treating COVID-19 Symptoms: A Randomized Trial","volume":"49","author":"Mahmud","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1002\/jmv.27122","article-title":"Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study","volume":"93","author":"Noor","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Popp, M., Reis, S., Schie\u00dfer, S., Hausinger, R.I., Stegemann, M., Metzendorf, M.I., Kranke, P., Meybohm, P., Skoetz, N., and Weibel, S. (2022). Ivermectin for Preventing and Treating COVID-19. Cochrane Database Syst. Rev., 6.","DOI":"10.1002\/14651858.CD015017.pub3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.chest.2021.03.003","article-title":"Standard Dose Ivermectin for COVID-19","volume":"159","author":"Buonfrate","year":"2021","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s10903-022-01386-w","article-title":"Strongyloidiasis Hyperinfection Syndrome in COVID-19 Positive Migrants Treated with Corticosteroids","volume":"24","author":"Jenks","year":"2022","journal-title":"J. Immigr. Minor. Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2020.13170","article-title":"COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection","volume":"324","author":"Stauffer","year":"2020","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e002321","DOI":"10.1136\/bmjgh-2020-002321","article-title":"Cost-Effectiveness of Different Strategies for Screening and Treatment of Strongyloides Stercoralis in Migrants from Endemic Countries to the European Union","volume":"5","author":"Shedrawy","year":"2020","journal-title":"BMJ Glob. Health"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:07Z","timestamp":1760124727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["v15051138"],"URL":"https:\/\/doi.org\/10.3390\/v15051138","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}